References

Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup

10.1002/alz.13859 · 2024 · External reference

New landscape of the diagnosis of Alzheimer's disease

10.1016/s0140-6736(25)01294-2 · 2025 · External reference

Evaluation of the revised criteria for biological and clinical staging of Alzheimer disease

10.1001/jamaneurol.2025.1100 · 2025 · External reference

Treatment for Alzheimer's disease

10.1016/s0140-6736(25)01329-7 · 2025 · External reference

Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics

10.1093/brain/awad188 · 2023 · External reference

Antiamyloid monoclonal antibody therapy for Alzheimer disease: emerging issues in neurology

10.1212/wnl.0000000000207757 · 2023 · External reference

New frontier, new challenges–recognizing and managing adverse effects of antiamyloid therapies

10.1001/jamainternmed.2025.2242 · 2025 · External reference

Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup

10.1002/alz.14338 · 2025 · External reference

Treatment-related amyloid clearance (TRAC): a framework to characterize patients in the era of anti-amyloid therapies

10.1002/alz.70997 · 2025 · External reference

Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial

10.1001/jama.2023.13239 · 2023 · External reference

Lecanemab in early Alzheimer's disease

10.1056/nejmoa2212948 · 2023 · External reference

ACR appropriateness criteria® dementia: 2024 update

10.1016/j.jacr.2025.02.031 · 2025 · External reference

Vascular cognitive impairment and dementia: clinical features, neuropathology, and biomarkers

10.1016/j.jacc.2025.11.008 · 2026 · External reference

Alzheimer disease anti-amyloid immunotherapies: imaging recommendations and practice considerations for monitoring of amyloid-related imaging abnormalities

10.3174/ajnr.a8469 · 2025 · External reference

The impact of amyloid and tau PET on Alzheimer disease diagnostics: AJR expert panel narrative review

10.2214/ajr.24.32325 · 2025 · External reference

The role of amyloid-β and tau PET in the new era of Alzheimer disease therapies

10.2967/jnumed.124.268339 · 2026 · External reference

Donanemab: appropriate use recommendations

10.1016/j.tjpad.2025.100150 · 2025 · External reference

Lecanemab: appropriate use recommendations

10.14283/jpad.2023.30 · 2023 · External reference

European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders

10.1016/s1474-4422(23)00447-7 · 2024 · External reference

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study

10.1016/s1474-4422(12)70142-4 · 2012 · External reference

The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET

10.1016/j.jalz.2014.07.003 · 2015 · External reference

Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology

10.1016/j.jalz.2018.09.001 · 2019 · External reference

Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer's disease

10.1186/s13195-020-00587-5 · 2020 · External reference

Added value of amyloid PET quantification with the Centiloid scale in clinical practice

10.3174/ajnr.a8850 · 2025 · External reference

Concordance between amyloid-PET quantification and real-world visual reads

10.1001/jamaneurol.2025.2218 · 2025 · External reference

A practical overview of the use of amyloid-PET Centiloid values in clinical trials and research

10.1016/j.nicl.2025.103765 · 2025 · External reference

Complementary utility of plasma biomarkers and Aβ-PET for diagnosis, risk-stratification, and treatment monitoring in Alzheimer's disease

10.1002/alz.70763 · 2025 · External reference

Precision pathways: optimising amyloid PET for sustainable Alzheimer's disease care

10.1007/s00415-026-13874-2 · 2026 · External reference

Cognitive phenotyping and interpretation of Alzheimer blood biomarkers

10.1001/jamaneurol.2025.0142 · 2025 · External reference

Plasma phosphorylated tau 217 and amyloid burden in older adults without cognitive impairment: a meta-analysis

10.1001/jamaneurol.2025.4721 · 2026 · External reference

Staging Alzheimer's disease through amyloid and tau PET

10.1093/brain/awaf346 · 2026 · External reference

Alzheimer's disease

10.1016/s0140-6736(26)00198-4 · 2026 · External reference

Blood biomarkers to detect Alzheimer disease in primary care and secondary care

10.1001/jama.2024.13855 · 2024 · External reference

Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

10.1016/s1474-4422(25)00227-3 · 2025 · External reference

Frequency and clinical outcomes associated with tau positron emission tomography positivity

10.1001/jama.2025.7817 · 2025 · External reference

Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging

10.1001/jamaneurol.2021.1858 · 2021 · External reference

Correlation of in vivo [18F]flortaucipir with postmortem Alzheimer disease tau pathology

10.1001/jamaneurol.2018.3692 · 2019 · External reference

Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes

10.1001/jamaneurol.2020.0528 · 2020 · External reference

Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials

10.1016/s1474-4422(22)00168-5 · 2022 · External reference

Evaluation of copathology and clinical trajectories in individuals with tau-clinical mismatch

10.1001/jamaneurol.2025.4974 · 2026 · External reference

Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER-ALZ randomized clinical trial

10.1001/jamaneurol.2022.2793 · 2022 · External reference

ACR-ACNM-ASNR-SNMMI practice parameter for the performance of brain PET/CT imaging in dementia

10.3174/ajnr.a9105 · 2026 · External reference

Global experience in brain amyloid imaging

10.1053/j.semnuclmed.2025.03.004 · 2025 · External reference

Identifying gaps and barriers in Alzheimer's disease and related dementia research and management in low- and middle-income countries: a survey of health professionals and researchers

10.3233/jad-240650 · 2024 · External reference

The current status of nuclear medicine in Africa

10.2967/jnumed.125.271248 · 2026 · External reference

Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias

10.1016/s1474-4422(20)30314-8 · 2020 · External reference

18F-FDG PET imaging in neurodegenerative dementing disorders: insights into subtype classification, emerging disease categories, and mixed dementia with copathologies

10.2967/jnumed.121.263194 · 2022 · External reference

Diagnostic and other biomarkers of dementia with Lewy bodies: from research to clinical settings

10.1016/s1474-4422(25)00314-x · 2025 · External reference

Diagnostic accuracy of amyloid versus 18 F-fluorodeoxyglucose positron emission tomography in autopsy-confirmed dementia

10.1002/ana.25968 · 2021 · External reference

FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease

10.1093/brain/awm177 · 2007 · External reference

FDG-PET patterns associated with underlying pathology in corticobasal syndrome

10.1212/wnl.0000000000007038 · 2019 · External reference

Diagnosis and treatment of Parkinson disease: a review

10.1001/jama.2019.22360 · 2020 · External reference

Emerging neuroimaging biomarkers across disease stage in Parkinson disease: a review

10.1001/jamaneurol.2021.1312 · 2021 · External reference

Neuropathologic validation and diagnostic accuracy of presynaptic dopaminergic imaging in the diagnosis of Parkinsonism

10.1212/wnl.0000000000209453 · 2024 · External reference

Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts

10.1002/mds.25975 · 2014 · External reference

Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB

10.1212/wnl.0000000000003512 · 2017 · External reference

Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels

10.1002/ana.410340304 · 1993 · External reference

β-Amyloid PET and 123I-FP-CIT SPECT in mild cognitive Impairment at risk for Lewy body dementia

10.1212/wnl.0000000000011454 · 2021 · External reference

The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia

10.1016/j.neurobiolaging.2020.12.009 · 2021 · External reference

Dopaminergic depletion, β-amyloid burden, and cognition in Lewy body disease

10.1002/ana.25707 · 2020 · External reference

18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies

10.1212/wnl.55.10.1575 · 2000 · External reference

Neuroimaging in low- to middle-income countries: a health equity perspective

10.3174/ajnr.a9098 · 2026 · External reference

Amyloid-related imaging abnormalities with emerging Alzheimer disease therapeutics: detection and reporting recommendations for clinical practice

10.3174/ajnr.a7586 · 2022 · External reference

A call for clinical trial globalization in Alzheimer's disease and related dementia

10.1002/alz.12995 · 2023 · External reference

Challenges and strategies in dementia care in the Philippines: global perspectives in neurology

10.1212/wnl.0000000000214032 · 2025 · External reference

Clinical practice recommendations of the Swiss Society for Neuroradiology: neuroimaging standards for enrollment and disease monitoring in anti-amyloid immunotherapies

10.1159/000549521 · 2026 · External reference

Susceptibility-weighted imaging is more reliable than T2*-weighted gradient-recalled echo MRI for detecting microbleeds

10.1161/strokeaha.113.002267 · 2013 · External reference

Clinical relevance of improved microbleed detection by susceptibility-weighted magnetic resonance imaging

10.1161/strokeaha.110.599837 · 2011 · External reference

MRI protocols and sequences for amyloid-related imaging abnormalities monitoring in Alzheimer's disease patients treated with monoclonal antibodies

10.1097/wco.0000000000001388 · 2025 · External reference

Cerebral amyloid angiopathy and Alzheimer disease – one peptide, two pathways

10.1038/s41582-019-0281-2 · 2020 · External reference

Using neuroimaging to study cerebral amyloid angiopathy and its relationship to Alzheimer's disease

10.3233/jad-230553 · 2024 · External reference

The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study

10.1016/s1474-4422(22)00208-3 · 2022 · External reference

CAA-ri and ARIA: two faces of the same coin?

10.3174/ajnr.a7759 · 2023 · External reference

Mixed brain pathologies account for most dementia cases in community-dwelling older persons

10.1212/01.wnl.0000271090.28148.24 · 2007 · External reference

Mixed pathologies and cognitive outcomes in persons considered for anti-amyloid treatment eligibility assessment: a community-based study

10.1212/wnl.0000000000214004 · 2025 · External reference

Vascular contributions to cognitive impairment and dementia in the United States: prevalence and incidence: a scientific statement from the American Heart Association

10.1161/str.0000000000000494 · 2025 · External reference

Neuroimaging standards for research into small vessel disease-advances since 2013

10.1016/s1474-4422(23)00131-x · 2023 · External reference

The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis

10.1136/bmj.c3666 · 2010 · External reference

Clinical significance of magnetic resonance imaging markers of vascular brain injury: a systematic review and meta-analysis

10.1001/jamaneurol.2018.3122 · 2019 · External reference

Regional growth rates of white matter hyperintensities are associated with beta-amyloid burden

10.1016/j.neurobiolaging.2025.12.006 · 2026 · External reference

White matter hyperintensity modulates the amyloid-tau-cognition association and anti-amyloid treatment efficacy in asymptomatic older adults

10.1002/alz.70990 · 2025 · External reference

Prevention of stroke in patients with silent cerebrovascular disease: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association

10.1161/str.0000000000000116 · 2017 · External reference

Delivering disease modifying treatments in Alzheimer's disease–an old age psychiatry UK perspective

10.1002/gps.6030 · 2023 · External reference

Imaging markers of vascular brain health: quantification, clinical implications, and future directions

10.1161/strokeaha.120.032611 · 2022 · External reference

Amygdalar and hippocampal volume loss in limbic-predominant age-related TDP-43 encephalopathy

10.1093/brain/awaf201 · 2025 · External reference

Utility of the amygdalar atrophy scale to identify patients with limbic-predominant age-related TDP-43 encephalopathy in a memory clinic

10.1212/wnl.0000000000214477 · 2026 · External reference

MRI signature of α-synuclein pathology in asymptomatic stages and a memory clinic population

10.1001/jamaneurol.2024.2713 · 2024 · External reference

Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations

10.1016/s1474-4422(21)00341-0 · 2022 · External reference

Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders

10.1001/jama.2018.12917 · 2018 · External reference

Arterial spin-labeled perfusion MRI in basic and clinical neuroscience

10.1097/wco.0b013e32832d9505 · 2009 · External reference

Functional imaging in Alzheimer's disease: a systematic review and meta-analysis of ASL-MRI and FDG-PET

10.1111/jon.70080 · 2025 · External reference

Cerebral hyperperfusion with lecanemab in Alzheimer's disease assessed by amyloid PET and arterial spin labeling

10.2174/0115672050453079260226065149 · 2026 · External reference

Brain-wide pathway for waste clearance captured by contrast-enhanced MRI

10.1172/jci67677 · 2013 · External reference

Perivascular spaces in the brain: anatomy, physiology and pathology

10.1038/s41582-020-0312-z · 2020 · External reference

Mapping water exchange across the blood-brain barrier using 3D diffusion-prepared arterial spin labeled perfusion MRI

10.1002/mrm.27632 · 2019 · External reference

Diffusion Tensor Image Analysis ALong the Perivascular Space (DTI-ALPS): revisiting the meaning and significance of the method

10.2463/mrms.rev.2023-0175 · 2024 · External reference

Glymphatic imaging: a critical look at the DTI-ALPS index

10.1007/s00234-023-03270-2 · 2024 · External reference

Evaluation and interpretation of DTI-ALPS, a proposed surrogate marker for glymphatic clearance, in a large population-based sample

10.1186/s13195-025-01842-3 · 2025 · External reference

Anatomically interpretable deep learning of brain age captures domain-specific cognitive impairment

10.1073/pnas.2214634120 · 2023 · External reference

Mapping human cortical areas in vivo based on myelin content as revealed by T1- and T2-weighted MRI

10.1523/jneurosci.2180-11.2011 · 2011 · External reference

High spatial overlap but diverging age-related trajectories of cortical magnetic resonance imaging markers aiming to represent intracortical myelin and microstructure

10.1002/hbm.26259 · 2023 · External reference

Trends and properties of human cerebral cortex: correlations with cortical myelin content

10.1016/j.neuroimage.2013.03.060 · 2014 · External reference

Arterial spin labelling perfusion MRI analysis for the Human Connectome Project Lifespan Ageing and Development studies

10.1162/imag_a_00444 · 2025 · External reference

Multimodal brain age estimates relate to Alzheimer disease biomarkers and cognition in early stages: a cross-sectional observational study

10.7554/elife.81869 · 2023 · External reference

A multi-modal parcellation of human cerebral cortex

10.1038/nature18933 · 2016 · External reference

Generation and evaluation of a cortical area parcellation from resting-state correlations

10.1093/cercor/bhu239 · 2016 · External reference

Human brain white matter atlas: identification and assignment of common anatomical structures in superficial white matter

10.1016/j.neuroimage.2008.07.009 · 2008 · External reference

The impact of traditional neuroimaging methods on the spatial localization of cortical areas

10.1073/pnas.1801582115 · 2018 · External reference

Artificial intelligence assistive software tool for automated detection and quantification of amyloid-related imaging abnormalities

10.1001/jamanetworkopen.2023.55800 · 2024 · External reference

AI-assisted detection of amyloid-related imaging abnormalities (ARIA): promise and pitfalls

10.3174/ajnr.a8946 · 2026 · External reference

Validity assessment of an automated brain morphometry tool for patients with de novo memory symptoms

10.3174/ajnr.a7790 · 2023 · External reference

Artificial intelligence-based rapid brain volumetry substantially improves differential diagnosis in dementia

2024 · External reference

An FDG-PET-based machine learning framework to support neurologic decision-making in Alzheimer disease and related disorders

10.1212/wnl.0000000000213831 · 2025 · External reference

A 3D convolutional neural network to classify subjects as Alzheimer's disease, frontotemporal dementia or healthy controls using brain 18F-FDG PET

10.1016/j.neuroimage.2024.120530 · 2024 · External reference

Automated differential diagnosis of dementia syndromes using FDG PET and machine learning

10.3389/fnagi.2022.1005731 · 2022 · External reference

FDA approval of artificial intelligence and machine learning devices in radiology: a systematic review

10.1001/jamanetworkopen.2025.42338 · 2025 · External reference

Ultrafast brain MRI protocol at 1.5 T using deep learning and multi-shot EPI

10.1016/j.acra.2023.04.019 · 2023 · External reference

Ultrafast brain MRI with deep learning reconstruction for suspected acute ischemic stroke

10.1148/radiol.231938 · 2024 · External reference

Deep learning-based acceleration in MRI: current landscape and clinical applications in neuroradiology

10.3174/ajnr.a8943 · 2026 · External reference

Ultra-fast MRI for dementia diagnosis and treatment eligibility: a prospective study

10.1002/alz.70341 · 2025 · External reference

Artificial intelligence-based image enhancement in PET imaging: noise reduction and resolution enhancement

10.1016/j.cpet.2021.06.005 · 2021 · External reference

AI for PET image reconstruction

10.1259/bjr.20230292 · 2023 · External reference

Artificial intelligence augmented cerebral nuclear imaging

10.1053/j.semnuclmed.2025.05.005 · 2025 · External reference

The Human Connectome Project's neuroimaging approach

10.1038/nn.4361 · 2016 · External reference

Abnormal white matter changes in Alzheimer's disease based on diffusion tensor imaging: a systematic review

10.1016/j.arr.2023.101911 · 2023 · External reference

Free-water diffusion tensor imaging improves the accuracy and sensitivity of white matter analysis in Alzheimer's disease

10.1038/s41598-021-86505-7 · 2021 · External reference

Glymphatic and meningeal lymphatic dysfunction in Alzheimer's disease: mechanisms and therapeutic perspectives

10.1002/alz.70709 · 2025 · External reference

Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease

10.1016/j.nicl.2019.101767 · 2019 · External reference

PET imaging of neuroinflammation in neurological disorders

10.1016/s1474-4422(20)30346-x · 2020 · External reference

Development of [18F]ACI-19626 as a first-in-class brain PET tracer for imaging TDP-43 pathology

10.1038/s41467-025-64540-6 · 2025 · External reference

Alpha-synuclein PET tracer development–an overview about current efforts

10.3390/ph14090847 · 2021 · External reference

Towards better interpretable and generalizable AD detection using collective artificial intelligence

10.1016/j.compmedimag.2022.102171 · 2023 · External reference

Hippocampal-amygdalo-ventricular atrophy score: Alzheimer disease detection using normative and pathological lifespan models

10.1002/hbm.25850 · 2022 · External reference

Performance characteristics of the NeuroEXPLORER, a next-generation human brain PET/CT imager

10.2967/jnumed.124.267767 · 2024 · External reference

A conformal TOF-DOI prism-PET prototype scanner for high-resolution quantitative neuroimaging

10.1002/mp.16223 · 2023 · External reference

Development and performance of SIAT bPET: a high-resolution and high-sensitivity MR-compatible brain PET scanner using dual-ended readout detectors

10.1007/s00259-023-06458-z · 2024 · External reference

Quantitative accuracy assessment of the NeuroEXPLORER for diverse imaging applications: moving beyond standard evaluations

10.2967/jnumed.124.268309 · 2025 · External reference

Remote MR scanning – a solution for shortage of skilled radiographers

10.1016/j.jmir.2023.05.046 · 2023 · External reference

Integrating global health initiatives into routine radiology workflow in the USA

10.1007/s10278-024-01356-8 · 2025 · External reference

Moving toward seamless interinstitutional electronic image transfer

10.1016/j.jacr.2021.11.017 · 2022 · External reference

Development of positron emission tomography radiotracers for imaging α-synuclein aggregates

10.3390/cells14120907 · 2025 · External reference

Amyloid and tau prediction of cognitive and functional decline in unimpaired older individuals: longitudinal data from the A4 and LEARN studies

10.14283/jpad.2024.122 · 2024 · External reference

Lifetime and 10-year absolute risk of cognitive impairment in relation to amyloid PET severity: a retrospective, longitudinal cohort study

10.1016/s1474-4422(25)00350-3 · 2025 · External reference